rs104886003
|
|
Colorectal Carcinoma
|
A |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
rs104886003
|
|
Megalencephaly cutis marmorata telangiectatica congenita
|
A |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
rs104886003
|
|
Seborrheic keratosis
|
A |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
rs104886003
|
|
Liver carcinoma
|
A |
0.720 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Liver carcinoma
|
C |
0.720 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Gallbladder Carcinoma
|
A |
0.720 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Gallbladder Carcinoma
|
C |
0.720 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Esophageal carcinoma
|
A |
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Mammary Neoplasms
|
C |
0.710 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Uterine Cervical Neoplasm
|
A |
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Esophageal carcinoma
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Uterine Cervical Neoplasm
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
|
23888070 |
2013 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
|
23066039 |
2013 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs104886003
|
|
ovarian neoplasm
|
A |
0.710 |
CausalMutation
|
CLINVAR |
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
22271473 |
2012 |
rs104886003
|
|
Mammary Neoplasms
|
C |
0.710 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs104886003
|
|
Mammary Neoplasms
|
C |
0.710 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
rs104886003
|
|
Mammary Neoplasms
|
C |
0.710 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
rs104886003
|
|
Mammary Neoplasms
|
C |
0.710 |
CausalMutation
|
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
rs104886003
|
|
Mammary Neoplasms
|
A |
0.710 |
CausalMutation
|
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |